The US Food and Drug Administration (FDA) has released updated draft guidance on continuous manufacturing (CM) for pharmaceutical drug substances, clarifying expectations around process validation, real-time release testing, and control strategy documentation.
Key updates include expanded guidance on multivariate process monitoring and clarified requirements for design of experiments documentation in regulatory submissions. The draft is open for comments until October 31, 2025.